Oxaliplatin
Recently, Kollmannsberger et al. [1] reported the final results of a phase II trial of oxaliplatin as a single agent in patients with relapsed or refractory non-seminomatous germ-cell tumors NSGCT ; treated from 1998 to 2001. The authors concluded that oxaliplatin is an active agent and that it should be evaluated in combination regimens. In fact, oxaliplatin has previously been studied in this set ting, and combination treatments are underway. Soulie et al. [2] reported a series of 13 patients who received an oxaliplatin-based regimen from 1992 to 1995 as part of a compassionate-use program for relapsed refractory NSGCT. Patients received oxaliplatin 130 mg m2 and cisplatin 100 mg m2, in combination with other drugs and alone. This study demonstrated that responses can occur in cisplatin-refractory patients four responses in eight patients ; using an oxaliplatin-based regimen. Furthermore, it provided information which showed that oxaliplatin can be safely combined with potentially active drugs in NSGCT. However, until the trial reported by the German group [1], there were no published data on singleagent use of oxaliplatin in NSGCT. From September 1997 to October 1999, eight patients with cisplatin-refractory n 6 ; or relapsed n 2 ; NSGCT also received single-agent oxaliplatin 130 mg m2 every 3 weeks ; at the Institut Gustave Roussy, Villejuif, France. These patients had received a median of two range one to four ; previous regimens. Among them, three out of eight achieved an improvement: one had a partial response with normalization of tumor markers, one had a partial response tumor markers were normal at baseline ; , and one had a reduction of 50% of serum human chorionic gonadotropin while on single-agent oxaliplatin. These data confirmed those of the German trial [1], showing activity in the advanced stages of the disease. A much higher activity of oxaliplatin is expected in combination regimens based on both preclinical data [3] and the clinical experience accumulated in other neoplasms [4, 5]. In certain models, synergy of oxaliplatin with other drugs and non cross-resistance with cisplatin are observed. This was the rationale for a French phase II trial of the oxaliplatin paclitaxel combination in relapsed refractory NSGCT, for which accrual is now over and first results are expected soon. Oxaliplatin was also combined with gemcitabine in a phase II trial conducted by the German group [6]. The overall.
By Ben J. Barnett, MD, The University of TexasHouston Medical School, & Mario Maldonado, MD, Baylor College of Medicine.
In the article by orabona et al entitled "toward the identification of a tolerogenic signature in ido-competent dendritic cells, " which appeared in the april 1, 2006, issue of blood volume 107: 2846-2854 ; , throughout the paper "ctl0-4-ig" should have been "ctla-4-ig.
Oxaliplatin online
F. intermedia Zabel F. suspensa F. viridissima ; Forsythia Relic of cultivation, and possibly a rare garden escape. 4, 6, 19. Ovens 1999, among shrubs on roadside I. Green ; . 6 Kilnamack 1997, by ruin P. Green and I. Green ; . 19 * Maynooth College, near southern boundary wall Bowering et al. 1995 ; . J. nudiflorum Lindl. Winter Jasmine 6 Ballygally East 2000, self-sown on wall of ruin in wood; Portlaw 2001, self.
Enchanters and upon all the Egyptians. But the Lord hardened the heart of Pharao, that he hearkened not unto them, as the Lord had said unto Moses. And the Lord said unto Moses: rise up early in the morning and stand before Pharao and tell him, thus saith the Lord God of the Hebrews: Let my people go, that they may serve me, or else I will at this time send all my plagues upon thine heart and upon thy servants and on thy people, that you mayst know that there is none like me in all the earth. For now I will stretch out my hand and will smite thee and thy people with pestilence: so that thou shalt perish from the earth. Yee in very deed for this cause have I stirred thee up, for to shew my power in thee, and to declare my name throughout all the world. If it be that thou stoppest my people, that thou wilt not let them go: behold, tomorrow this time, I will send down a mighty great hail: even such one as was not in Egypt since it was grounded unto this time. Send therefore and fetch home thy beasts and all that thou hast in the field. For upon all the men and beasts which are found in the field and not brought home, shall the hail fall, and they shall die. And as many as feared the word of the Lord among the servants of Pharao made their servants and their beasts flee to house: and they that regarded not the word of the Lord, left their servants and their beasts in the field. And the Lord said unto Moses: stretch forth thine hand unto heaven, that there may be hail in all the land of Egypt: upon man and beast, and upon all the herbs of the field in the field of Egypt. And Moses stretched out his rod unto heaven, and the Lord thundered and hailed, so that the fire ran along upon the ground. And the Lord so hailed in the land of Egypt, that.
Portance in host defense, the microbicidal mechanisms of human PMNs have been examined closely. Mammalian PMNs use three general mechanisms to kill ingested microbes. The relative contributions of these mechanisms differ considerably from species to species. While one mechanism utilizes peptides and proteins, two of the mechanisms are oxidative in nature. One of these oxidative modes involves the assembly of a multi-component NADPH oxidase complex that reduces molecular oxygen univalently to superoxide O2 ; anions Nauseef, 1999; Babior, 1999 ; . The other, which is mediated by an inducible, multi-component nitric oxide synthase iNOS ; , is less prominent in human PMNs than the NADPH oxidase system Murray and Nathan, 1999; Nathan and Shiloh, 2000 ; . We are unaware of data concerning the presence or absence of NADPH oxidase and iNOS in tunicate hemocytes. Phenoloxidase, an enzyme that can generate H2O2, is present in the ``morula cells'' of Styela plicata Cammarata et al., 1997 ; and of Botryllus schlosseri Ballarin et al., 1998 ; . The superoxide anions generated by NADPH oxidase are unstable and undergo secondary reactions, including dismutation to hydrogen peroxide. H2O2 is more stable than superoxide and has modest antimicrobial properties, but it can be degraded rapidly by catalase, an enzyme found in erythrocytes and many bacteria. However, PMNs transform H2O2 into more potent oxidants in several ways, one of which involves myeloperoxidase. When provided with chloride and H2O2, myeloperoxidase catalyzes the formation of molecules indistinguishable from the hypochlorite found in Clorox bleach Klebanoff, 1999 ; . This nascent bleach can also react with primary or secondary amines to form longer lasting, antimicrobial chloramines Weiss et al., 1983 ; . In addition to its reactions with myeloperoxidase, H2O2 can interact with divalent iron in a Fenton reaction that generates hydroxyl radicals Wardman and Candeis, 1996 ; . The highly reactive hydroxyl radicals are potent microbicides. In certain species, especially rodents, macrophages have an inducible nitric oxide synthase complex iNOS ; that can generate large amounts of nitric oxide--a strong oxidant with antimicrobial properties. In many rodent models, the ability to produce nitric oxide is critical in allowing macrophages to deal with diverse pathogens, organisms ranging from trypanosomes Murray and Nathan, 1999 ; to mycobacteria Bekker et al., 2001 ; . Because macrophages lack storage pools and oxandrolone.
Protesters In Haiti's Capital Demand Aristide's Return Nasdaq February 9, 2007 PORT-AU-PRINCE, Haiti AP ; --Hundreds of supporters of ousted former president Jean-Bertrand Aristide protested outside the U.N. peacekeeping mission Wednesday, demanding the exiled leader's return and accusing blue-helmeted troops of killing civilians. Protesters shouted "Down with the U.N.!" as they marched from a downtown slum and gathered outside the U.N. mission's hilltop headquarters, where they shouted at U.N. soldiers and Haitian police guarding the fortified complex. "We want the international community to hear our voice when we say we want Aristide back, " Jacques Bloncourt, 48, said as he held aloft a photograph of the former leader, who is currently in exile in South Africa. Aristide, a former slum priest turned president, fled the Caribbean nation in February 2004 amid a three-week rebel uprising. He later accused the U.S. of kidnapping him in a coup - a charge Washington denies. Many of the protesters came from the seaside slum of Cite Soleil, an Aristide stronghold where armed gangs and U.N. peacekeepers clash almost daily. The protesters said civilians are often killed in gunbattles started by peacekeepers and accused President Rene Preval of allowing it to happen. "President Preval lets them kill us, " Cite Soleil resident Fredrick Dubois said. The 9, 000-strong U.N. peacekeeping force arrived in July 2004 to quell violence after Aristide's ouster but has struggled to root out gangs based in Port-au-Prince's dense slums. The U.N. mission says troops only fire when attacked. The march coincided with the 21st anniversary of the ouster of former dictator Jean Claude "Baby Doc" Duvalier, whose departure paved the way for Haiti's first free elections in December 1990, which Aristide won in a landslide. Aristide was ousted a year later in a military coup but returned to power in 1994 after 20, 000 U.S. troops came to Haiti to halt an exodus of boat people to Florida and restore democracy.
Eyedrops must be administered correctly to lower IOP. In a SCH study, several criteria were used to evaluate eyedrop administration technique in ambulatory glaucoma patients. The criteria were evaluated before and after pharmacist demonstration. All patients who completed a follow-up visit n 17 ; had improved technique after pharmacist intervention. Table I and oxaprozin.
2005; 8-13 2 gamelin l, boisdron-celle m, delva r, et al prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer.
As first-line treatment for advanced colorectal cancer, patients treated with oxaliplatin 5-fu lv had significantly longer progression-free-survival median, 9 vs 2 months ; and better overall response rates 5 7% vs 2 3% ; when compared with the control arm of 5-fu lv and oxazepam.
To be as high as 3% and may be much more common than originally thought [5] The use of fluoropyrimidines in patients with this metabolic defect is associated with a very high mortality [3]. A standard salvage treatment for the underlying malignancy in patients with inherited DPD-deficiency is yet to be defined. The camptothecine derivative irinotecan, a DNA topoisomerase I-inhibiting agent, was shown to have activity against colorectal cancer [6]. The drug lacks cross-resistance with 5-FU and is now commonly used for first- or second-line treatment of metastatic disease Oxaliplatin, a diaminocyclohexane platinum derivative, has impressive anticancer activity when used in combination with 5-FU and fohnic acid as first-line chemotherapy, and activity has also been seen when used as single agent in this tumor type [7]. Raltitrexed, a quinazoline folate analogue, was developed as a direct and specific thymidylate synthase inhibitor that lacks the non-specific effects on RNA and protein synthesis which are often observed for 5-FU [8]. Raltitrexed is now available for treatment of colorectal cancer in many countries. All these novel agents could be considered as salvage treatment options for patients with defects in the 5-FU metabolism related to DPD deficiency. This case report describes the sequential palliative use of single-agent irinotecan, oxaliplatin and raltitrexed in a partially DPD-deficient patient with a hepatic relapse of colorectal cancer, who experienced hfe-threatening 5-FU-related toxicity during standard adjuvant chemotherapy.
Oxaliplatin online
Original received March 5, 2002; resubmission received September 11, 2003; revised resubmission received October 15, 2003; accepted October 15, 2003. From the Alfred and Baker Medical Unit M.K., K.S., J.P.F.C.-D. ; , Wynn Domain, Baker Medical Research Institute, Prahran, Victoria, Australia; and Prince Henry's Medical Research Institute M.J., E.S. ; , Clayton, Victoria, Australia. Correspondence to Jaye Chin-Dusting Alfred and Baker Medical Unit Baker Medical Research Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria 8008 Australia. E-mail j.chin alfred .au 2003 American Heart Association, Inc. Circulation Research is available at : circresaha DOI: 10.1161 01.RES.0000103172.98986.25 and oxymorphone.
In November 2003 Novo Nordisk convened the Second International DAWN Summit in London in which some 150 decisionmakers, healthcare professionals and people with diabetes from 31 countries issued a `call to action', stating that diabetes care across the world must change to take into account the huge psychological impact of diabetes. Many of the summit participants have already put the call to action into practice. In addition, Novo Nordisk affiliates and our partners have initiated many national activities. In Poland and India, nationwide activities based on DAWN are already changing the approach to diabetes care. Activities are being started in.
Each age group show remarkable similarity, with the exception of pH and NH4 ; within each age group, a higher pH and NH4 + concentration were observed in the CF subgroup. These differences were not statistically significant, however, most likely due to the limited data for each age group. Results obtained for the CF and CS subgroups, respectively, for the different age groups from different communities ; again show remarkable similarities in plaque fluid composition, although differences in Na + and Cl- concentrations are apparent; substantially lower levels of Na + and Cl-' were found in the 1417-year-old age group for both the CF and CS subgroups and oxytocin.
Ann oncol 2003; 78-138 zeuli m, di costanzo f, sdrobolini a, gasperoni s, paoloni fp, carpi a, moscetti l, cherubini r, cognetti capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
The Alkaptonuria Society was set up to tackle these problems. It aims to raise awareness about Alkaptonuria among patients, their families, the public, and the medical profession, and to fund research to help find a cure to this serious and rare disease and paclitaxel.
Figure 7. Splenocytes from mice passively transferred with IgG from hMOR CHO-injected mice are sensitized to CD95-mediated apoptosis. One hundred g of purified serum IgG from mice injected with either PBS ; or CHO cells ; or recombinant hMOR CHO cells ; were intravenously transferred into naive BALB c mice. Twenty four hours later, IgG-injected mice were sacrificed. The figure shows the percentage of subdiploid nuclei when splenocytes were incubated in the presence of anti-Fas monoclonal IgG antibody Jo2 for 24 hours. Nuclei DNA peak was analyzed by cytofluorometry after incubation of the cells in hypotonic medium containing propidium iodide. Each experience was performed in duplicates. Basal apoptosis of splenocytes in absence or in presence of hamster anti-KLH monoclonal IgG antibody was 8 + 2.
J. M. Espie. M. Calvo. F. Feriiie. C. Mignot. I study of oxaliplatin in patients with advanced Pharmacol., C., Bleiberg. 25: 299-303, 1990. H. Gamelin and palonosetron.
Dr. Stephenson: It seems like bevacizumab has made its way into the lexicon pretty quickly. Maybe it's just because we're excited about its mechanism of action and the fact that it has shown activity. I think most oncologists are aware of its use in colorectal cancer. After last year's ASCO American Society of Clinical Oncology ; meeting, it's become almost standard of care. To a lot of physicians, if you've got a patient with metastatic colorectal carcinoma at presentation, you are likely to start with a FOLFOX- or FOLFIRI-based regimen. Our partners would all choose FOLFOX plus bevacizumab as front-line therapy. Dr. O'Rourke: We generally have been using a modified FOLFOX regimen in combination with bevacizumab as first-line therapy for metastatic disease. I have also given bevacizumab plus CapeOx, which seems to be pretty well tolerated, too. Historically, bevacizumab was tested with regimens containing 5FU LV or irinotecan, and there was good evidence that it enhanced the effect of both. I think community oncologists believed that it was probably also effective with oxaliplatin 5-FU regimens. I tend to use bevacizumab in patients I've seen recently because it makes sense that it would enhance the effect of those agents. Dr. Rinaldi: Results from published trials support the use of bevacizumab in combination with irinotecan or oxaliplatin for front-line treatment of metastatic disease. Data from the TREE trials reinforce the belief that this agent does not significantly add to the toxicity of these regimens. An interesting question is how should we treat patients who respond to such bevacizumab-based regimens.
4 national institute for clinical excellence, guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer and pamidronate.
In general in this sector, the BAT for oxides of nitrogen expressed as NO2 ; is considered to be the use of oxy-fuel melting. The emission level associated with BAT is considered to be 0.5 1.5 kg tonne of glass melted or alternatively 500 - 700 mg Nm3, if conventional air-gas systems are able to achieve this level with primary or secondary measures. It is acknowledged that these performance levels represent a significant improvement over current performance for many continuous furnaces, and therefore could represent medium term proposals for such furnaces. There are no overriding technical obstacles to the achievement of the emission levels stated above, and given the necessary time for the development and implementation of the appropriate techniques this figure should be achievable.
1. Pfeffer MA, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992; 327: 669 van Kats JP, Danser AHJ, van Meegen J, et al. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation. 1998; 98: 73 Campbell DJ, Kladis A, Duncan AM. Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension. 1993; 22: 513522 and papaverine and oxaliplatin.
The Nephrology Division at the University of Iowa was formally initiated in 1970 as the Renal-Hypertension-Electrolyte Division under the direction of Dr. Walter Kirkendall. Since that beginning, the division has assumed additional responsibilities for the medical direction of organ transplantation and has simplified its name. Its current 16 faculty members share clinical responsibilities for the care of patients at the University of Iowa Hospitals and Clinics and the Iowa City VA Medical Center. Postdoctoral fellows having trained in the Iowa nephrology program number over 75. with about one fourth of the fellows being involved in only research training. The current nine trainees have interests that reflect the diverse areas of expertise of the Nephrology Division: membrane transport, cell and molecular biology, integrated renal physiology, clinical trials, and epidemiology. The clinical programs in nephrology at the University of Iowa offer a full and vigorous opportunity for clinical training. The dialysis program offers a balanced population of 52 center hemodialysis patients. 42 home hemodialysis patients, and 40 home peritoneal dialysis patients. Last year, nephrology transplant physicians assisted in the care of 85 patients receiving a kidney transplant in addition to caring for others who received heart, lung, liver, and pancreas transplants. Division physicians performed over 100 renal biopsies and 1.500 consultation visits and attended to over 600 admissions to the renal medicine inpatient unit. We are pleased to have the opportunity to be a part of this educational initiative by JASN.
Systems based on large family of many-valued logics. The proofs use as a tool certaing relational inequalities that we call BK-Residuated Bootstrap. In computer science, fuzzy relational equations in monoidal logics have applications in specificaton of computing systems by means of their behavioral characteristics as well as in computing with words and parnate.
ASCO Gastrointestinal Cancers Symposium; Abstract no 252 103 Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-8040 Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLead HL, Mulcahy MF, Schilsky R, Goldberg R. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine G ; plus bevacizumab B ; versus gemcitabine plus placebo P ; in patients pts ; with advanced pancreatic cancer PC ; : A preliminary analysis of Cancer and Leukemia Group B CALGB ; 105 Kim GP, Oberg A, Kabat B, Sing A, Hedrick E, Campbell D, Alberts S. NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2006; 24: 4113 Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002; 99: 11399-11404 Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398 Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular endothelial growth factortrap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9: 5721-5728 H u a McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003; 100: 7785-7790 Dupont J, Rothenberg ML, Springs DR, Cedarbaum JM, Furfine ES, Cohen DP, Dancy I, Lee HS, Cooper W, Lockhart AC. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2005; 23: 3029 Rixie O, Verslype C, Meric JB, Tejpar S, Bloch J, Crabbe M, Khayat D, Furfine ES, Assadourian S, Van Custem E. Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin I-LV5FU2 ; in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2006; 24: 13161 Mulay M, Limentani SA, Carroll M, Furfine ES, Cohen DP, Rosen LS. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 2006; 24: 13061 Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF MEK ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972 Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D. Results of.
Watchem, Timothy, pseud. War-horseiana; or, An authentic report of the sayings and doings of the war-horse and his ponies; from the year 1847 up to the present time. [Philadelphia?]. 1851 Containing their speeches, resolutions, toasts, adventures, communications, dances, songs, etc.; Illustrated with eight beautiful engravings, by Peppergrass, from designs by Cruikshank.; 48 p.; front., plates.; 23 cm.; A piece of campaign literature satirizing Reah Frazer "The Lancaster war-horse", a prominent Democratic politician. Reel: 180, No. 3278 Waterbury, Jared Bell, 1799-1876. The brighter age: a poem. Boston, Crocker & Brewster. 1830 94 p.; 19 cm. Reel: 144, No. 2459 Waterous, Timothy. The battle-axe, and weapons of war. Groton. 1841 being a treatise fitted to the present day . 2ed.; 86 p.; 28 cm. Reel: 144, No. 2460 Waterston, Anne Cabot Lowell Quincy ; , "Mrs. R.C. Waterston". Verses. Boston. 1863 vi p., 1 l., 74 p., 1 l.; 18 cm. Reel: 180, No. 3279 Waterston, Robert Cassie, 1812-1893. A poem, delivered before the Mercantile library association, at their twenty-fifth anniversary, October 15, 1845. Boston, Press of T.R. Marvin. 1845 20 p.; 23.5 cm. Reel: 144, No. 2461 Waterston, Robert Cassie, 1812-1893. Thought on moral and spiritual culture. Boston. 1844 2ed. rev., ; 302 p.; 17 cm. Reel: 144, No. 2463 Waterston, Robert Cassie, 1812-1893. Thoughts on moral and spiritual culture. Boston, Crocker & Ruggles, etc. 1842 viii, 317 p.; 18 cm. Reel: 144, No. 2462 Waterston, Robert Cassie, 1812-1893. The true position of the church in relation to the age. Boston, W. Crosby & H.P. Nichols. 1847 A discourse delivered at the dedication of the Church of the Saviour, Wednesday, November 10, 1847.; Published by request.; 40 p.; 22 cm. Reel: 144, No. 2464 Waterston, Robert Cassie, 1812-1893. The widow's son: a sketch from real life. Boston, J. Munroe and company. 1843 14 p.; 22 cm. Reel: 144, No. 2465 Watrous, Sophia. The gift; or, Miscellaneous poems. Montpelier, E.P. Watton and sons. 1841 172 p.; 13 cm. Reel: 144, No. 2466 Watson, Adelaide H. Poems. [n.p.]. [1867] 35, [1] p.; 35 p.; Cover title: Fancies. Reel: 181, No. 3280 Watson, Henry Cood, 1816-1875, tr. Giovanna Ima di Napoli, drama lirice in tre atti. New York. c1850 57 p. Reel: 145, No. 2468 Watson, Henry, b. 1813?. Narrative of Henry Watson, a fugitive slave. Boston, B. Marsh. 1848 48 p.; illus.; 19 cm. Reel: 145, No. 2467 Watson, John Davis. Castalian dews, a random selection from the fugutive poems of "Harlequin, ". Baltimore, W. Taylor. 1849 144 p.; 16 cm. Reel: 145, No. 2469 Watson, John Whittaker, 1824-1890. Beautiful snow, and other poems. Philadelphia, Turner brothers & co. [1869] 100, [2] p.; 18 cm.; Fifth edition. cf. Publisher's notice.; Authorship of "Beautiful snow" falsely claimed by several persons. cf. Publisher's notice. Reel: 181, No. 3282 [Watson, John Whittaker] 1824-1890. Beautiful snow. [London, Ford & Shapland, printers]. [186-?] [4] p.; 13 cm.; Leaflet of "The Midnight meeting movement, 2 Red Lion Square, London, W.C.". Reel: 181, No. 3281 Watterston, George, 1783-1854. The child of feeling. George Town, Published by Joseph Milligan, Dinmore and Cooper, printer. 1809 A comedy in five acts.; 113 p. Reel: 73, No. 2124 Watts, Anna Mary Howitt ; , Mrs., 1824-1884. Poetical tales for good boys and girls. Worcester [Mass.] Edward Livermore. 1850 [c1847] 72 p.; illus.; 14 cm. Reel: 145, No. 2470.
1. Cohen AM, Minsky BD, Schilsky RL. Colon Cancer. In De Vita VT, Hellman S, Rosenberg SA eds ; : Principles and Practice of Oncology. Philadelphia: J.B. Lippincott 1993; 929-77. 2. Moertel CG, Fleming TR, MacDonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8. Wolmark N, Rockette H, Wickerham L et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993; 11: 1879-87. O'Connell MJ, Maillard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of Fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903. Kemeny N, Israel K, Niedzwiecki D et al. Randomized study of continuous infusion fluorouracil vs. fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer. J Clin Oncol 1990; 8: 313-8. TashiroT, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato trans-l-l, 2-diaminocyclohaxane ; platinum II ; : New experimental data. Biomed Pharmacother 1989; 43: 251-60. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303. Machover D, Diaz-Rubio E, De Gramont A et al. Two consecutive phase II studies of oxaliplatin L-OHP ; for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment withfluoropyrimidines.Ann Oncol 1996; 7: 95-8. Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulate rate. Eur J Cancer 1993; 29A: 1280-4. Becouam Y, Ychou M, Ducreux M et al. Oxaliplatin L-OHP ; as first-line chemotherapy in metastatic colorectal cancer MCRC ; patients: Preliminary activity toxicity. Proc Soc Clin Oncol 1997, 16: 229a. Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 Irinotecan ; in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1283-7. Rougier P, Bugat R, Douillard JYet al. Phase II of Irinotecan in the treatment of advanced colorectal cancer in chemotherapynaive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60. Cunningham D, Zalcberg J, Smith IE et al. 'Tomudex': A novel thymidylate synthethase TS ; inhibitor with clinical antitumour activity in a range of solid tumors. Ann Oncol 1994; 5 Suppl 8 ; : 179. 15. Cunningham D, Zalcberg J, Rath U et al. Final results of a randomised trials comparing 'tomudex' ratiltrexed ; with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-5. Received 7 August 1997; accepted 14 October 1997.
Committee IRC ; , blinded to the treatment arms, assessed both the progression on prior irinotecan and the response to protocol treatment for all patients. Of the 329 randomized patients, 206 63% ; were male. The median age was 59 years range 26-84 ; , and the majority was Caucasian 323, 98% ; . Eighty-eight percent of patients had baseline Karnofsky Performance Status 80. Fifty-eight percent of patients had colon cancer and 40% rectal cancer. Approximately two-thirds 63% ; of patients had previously failed oxaliplatin treatment. The efficacy of ERBITUX plus irinotecan or ERBITUX monotherapy was evaluated in all randomized patients. Analyses were also conducted in two pre-specified subpopulations: irinotecan refractory and irinotecan and oxaliplatin failures. The irinotecan refractory population was defined as randomized patients who had received at least two cycles of irinotecan-based chemotherapy prior to treatment with ERBITUX, and had independent confirmation of disease progression within 30 days of completion of the last cycle of irinotecan-based chemotherapy. The irinotecan and oxaliplatin failure population was defined as irinotecan refractory patients who had previously been treated with and failed an oxaliplatin-containing regimen. The objective response rates ORR ; in these populations are presented in Table 1. Table 1: Objective Response Rates per Independent Review.
A total of 2542 titles and abstracts were screened for inclusion in the review of clinical and costeffectiveness; 194 studies were ordered as full papers and assessed in detail. Nine RCTs were identified. In five of these trials, both the comparators were used within their licensed indications. Of these five trials, three of the trials included participants with both platinumresistant and platinum-sensitive advanced ovarian cancer, and a further two trials only included participants with platinum-sensitive disease. The comparators that were assessed in the three trials that included both subtypes of participants were PLDH versus topotecan, topotecan versus paclitaxel and PLDH versus paclitaxel. In the further two trials that included participants with the subtype of platinum-sensitive disease, the comparators that were assessed were singleagent paclitaxel versus a combination of cyclophosphamide, doxorubicin and cisplatin CAP ; and paclitaxel plus platinum-based chemotherapy versus conventional platinum-based therapy alone. A further four trials were identified and included in the review in which one of the comparators in the trial was used outside its licensed indication. The comparators assessed in these trials were oxaliplatin versus paclitaxel, paclitaxel given weekly versus every 3 weeks, paclitaxel at two different dose levels and oral versus intravenous topotecan and oxandrolone.
I figured i was in for another dose of eyewash on the miracles of erbitux, oxaliplatin and avastin.
Alarm This system sounds an audible and possibly visual warning when the vehicle is tampered with. Battery Back Up A siren that has its own battery, which allows the alarm to continue to sound even if the car battery is disconnected. Bonnet Locks These lock the bonnet of the car, preventing thieves from attacking the engine compartment. Coded Audio Equipment ICE The radio stereo has a secret code, which stops the radio from working if stolen. Coded Fuel Valve This valve shuts off the fuel supply to the engine and requires a sophisticated code to run the vehicle. Ideal for diesels. Dead Locking This disables the normal lock functions and prevents a thief opening the car from the inside by breaking the window and operating the release handle or button. DIY Security Markings You - the vehicle owner, can mark your name and address in hidden parts of the vehicle, e.g. inside door skins, under the seat frames, using Dymo tape, ultraviolet pens, cards or similar. This helps to identify stolen vehicles. Glass Break Detector This sets off the alarm if a thief breaks a car window. Glass Etching All the glass on the vehicle, sometimes including headlamps, is etched with the vehicle's registration number and or Vehicle Identification Number. Immobiliser An immobiliser stops the vehicle from being driven away. There are two types: 1. Mechanical: These lock either the steering wheel, gear lever or pedals in position. 2. Electronic: These disable the vehicle's electrical system and engine. Inclination Sensor This sets off the alarm when it senses the vehicle is being raised or jacked up to tow the vehicle away or steal the wheels. Microwave Sensor A volumetric sensor designed to reduce the possibility of false alarms on soft top vehicles. Paging A paging device sends a signal to the owner, telling him the car is being attacked or stolen.
An update of guidance issued in 2002. Irinotecan and oxaliplatin are accepted for use as treatment options but raltitrexed should only be used within clinical trials.
Oxaliplatin online
Dogenous NO production on the vasoconstrictive actions of ET-1. Although our approach does not distinguish the endogenous mechanisms normally used in intracavernosal pressure maintenance, it does suggest a dual action of NO where NO can directly relax cavernosal smooth muscle and can interfere with the constrictive action of ET-1; both actions could then contribute to the erectile response. Perspectives The studies presented here support the hypothesis that a balance between the actions of ET-1 and NO regulates penile blood flow and penile erection. It is generally believed that an imbalance between the actions of NO and ET-1 contributes to vascular dysfunction 11, 12 ; and could be responsible for some forms of erectile dysfunction 30 ; . For example, in both diabetic and nondiabetic men, there was a significantly higher level of ET-1 in cavernosal blood and peripheral blood in patients with erectile dysfunction than in those without erectile dysfunction 22 ; . These authors suggest that local release of ET-1 during the early stages of atherosclerosis could also contribute to pathogenic changes in the cavernosal tissue and result in erectile dysfunction.
The lc , defined as the drug concentration that results in 50% lcs, was derived by calculating the point where the dose-response curve crosses the 50% lcs point.
144. CameronJL, Gayler BW, Sanfey H, et al. Sclerosing cholangitis: anatomical distnibution of obstructive lesions. Ann Surg 1 984.
U Uchitomi Y, see Akechi T Ueno NT, see Escalon MP see Hamaoka T Ueno NT, Shpall EJ, Champlin RE, Jones RB. Graft-Versus-Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier editorial ; , 3846 Ueoka H, see Hotta K Ullrich R, see Daum S Ulm K, see Gertler R Ulrich CM, see Robien K Undevia SD, see Innocenti F Uner A, see Altundag O Unterhalt M, see Lenz G Uribe N, see Fernandez-Martos C Urioste M, see Valle L Urkin J, see David YB Ursin G, Palla SL, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Greendale GA. Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen Progestin Interventions PEPI ; Trial, 2842 Urtasun R, see Roa W.
Patients were evaluated at baseline, week 3, and week 15. Primary end points were the changes from baseline to week 15 in distance walked in 6 minutes and the change in quality of life as measured by the Short Form Health Survey SF-36 ; questionnaire. A 6-minute walking test was carried out under standardized conditions20 and by investigators who were blinded to the clinical data and group assignment of the patients. All patients were familiar with the 6-minute walking test and cardiopulmonary exercise testing. Health-related quality of life was assessed with the SF-36, which consists of 36 items representing 8 subscales that cover the domains of physical functioning, role functioning physical, bodily pain, general health perception, vitality, social functioning, role functioning emotional, and mental health.21 The 8 subscales range from 0 to 100 higher scores indicating better quality of life ; and are summarized by 2 summation scales, the physical component scale and the mental component scale. The completed questionnaire at baseline was compared with the results after 15 weeks by investigators who were blinded to the patients' clinical data and group assignment. Secondary end points were changes in WHO functional classification, Borg scale 6 no exertion, 20 maximal exertion ; 22 assessed immediately after completion of the stress Doppler echocardiography, and parameters of echocardiography and gas exchange. Stress Doppler echocardiography was carried out at rest and during supine bicycle exercise as described previously.23, 24 Systolic pulmonary artery pressures PASPs ; were estimated from tricuspid regurgitation velocity. The right ventricular and atrial areas were obtained in apical 4-chamber views through planimetry. Cardiopulmonary exercise testing was performed during the stress Doppler echocardiographic examination with cycle ergometer ER 900, Ergoline GmbH, Bitz, Germany ; and a cardiorespiratory diagnosis system Oxycon Alpha, Erich JAEGER GmbH & Co., Hoechberg, Germany ; . Workload, heart rate, ventilation VE ; , oxygen uptake, and carbon dioxide output VCO2 ; were measured continuously. The anaerobic threshold was detected with the V-slope method.25 All recordings of echocardiography and cardiopulmonary exercise testing were analyzed again offline in random order and in a blinded fashion.
Pharmacokinetic analyses were performed only on patients at the MTD level. On week 1 of cycle 1, irinotecan pharmacokinetic analyses were conducted over 24 h at 0, 0.5, 1, 3, and 24 h after irinotecan infusion. On week 4 of cycle 1, one sample was collected before oxaliplatin infusion for platinum baseline only ; . Additional samples were collected for both irinotecan and oxaliplatin analyses at the end of oxaliplatin infusion and coinciding with the start of irinotecan infusion and 0.5 h after oxaliplatin infusion coinciding with the end of irinotecan infusion samples were also collected at 1, 3, 5 and 24 h after the oxaliplatin infusion. All blood samples 5 ml each ; were collected into heparinized containers and kept on ice throughout the procedure and underwent ultrafiltration within 12 h of sample collection. Ultrafiltrable platinum was obtained from plasma after centrifugation with a Centrifree 30 000-Da micropartition device Amicon Bioseparations, Millipore Corporation, Bedford, MA, USA ; and shipped to Sanofi Synthelabo Pharmaceuticals for platinum analysis. Another sample was analyzed for irinotecan and irinotecan metabolites SN38 and SN38G ; at MSKCC. The pharmacokinetics of platinum were evaluated in plasma ultrafiltrate samples by an inductively coupled plasma mass spectrometry method [18]. Irinotecan, SN-38, and SN-38G were assayed using high-performance liquid chromatography with fluorometric detection, according to previously published techniques [19, 20].
In the dexrazoxane arm, dexrazoxane was granted accelerated rather than regular approval for use only after patients had received a cumulative doxorubicin dose of 300 mg m2. The sponsor was required to demonstrate that continued treatment with doxorubicin and coadministration of dexrazoxane resulted in clinical benefit compared with ending doxorubicin therapy at a cumulative dose of 300 mg m2. Although the study was initiated, it was terminated after 3 years because of poor accrual. Dexrazoxane was subsequently granted regular approval on the basis of evidence from the literature 1218 ; , including a metaanalysis of five studies that evaluated the benefit of continued anthracycline use. In 2001, imatinib mesylate Gleevec ; was granted accelerated approval for the treatment of chronic myelogenous leukemia CML ; in blast crisis, in accelerated phase, or in chronic phase after progression on interferon IFN ; treatment. Approval was granted on the basis of results from three single-arm studies 19, 20 ; conducted in patients with Philadelphia chromosome positive CML. A total of 1027 patients were enrolled on the studies, which evaluated cytogenetic response rate CML chronic phase ; and hematologic response rate CMLaccelerated phase and CML blast crisis ; as primary endpoints. The cytogenetic response rate for patients with CML chronic phase 49% to 57% ; , and the hematologic was 53% 95% CI response rates for patients with CMLaccelerated phase and CML blast crisis were 69% 95% CI 63% to 75% ; and 31% 95% CI 25% to 37% ; , respectively. In addition to providing safety and efficacy follow-up of the three single-arm studies, the sponsor also committed to complete a randomized phase III study comparing imatinib to a combination of IFN plus cytarabine in patients with newly diagnosed CML. This randomized study, which was open to enrollment from June 2000 to January 2001, has been completed and submission of its findings has resulted in the accelerated approval of imatinib for first-line treatment of CML. In 2003, accelerated approval of imatinib mesylate for the treatment of CML in blast crisis, in accelerated phase, or in chronic phase after IFN therapy was converted to regular approval on the basis of the submission of follow-up data. All 532 patients with chronic phase CML were in late chronic phase, with a median time from diagnosis to last follow-up of 32 months. A complete hematologic response rate was achieved in 95% CI 92.3% to 96.3% ; of the patients. The confirmed major cytogenetic response rate was 60% 95% CI 55.3% to 63.8% ; . An estimated 87.8% of patients who achieved a major cytogenetic response maintained the response for 2 years after the initial response. After 2 years of treatment, estimated overall survival was 90.8% 95% CI 88.3% to 93.2% ; . Hematologic response rates for patients with blast crisis CML and accelerated phase CML were similar to those observed in the initial interim analyses described above. The median duration of hematologic response was 10 months for patients in blast crisis and 28.8 months for patients in accelerated phase. In 2002, oxaliplatin Eloxatin ; was granted accelerated approval for use in combination with 5-FU LV on the basis of data from a randomized, three-arm study of oxaliplatin plus infusional 5-FU LV versus 5-FU LV alone versus single-agent oxaliplatin in patients with advanced colorectal cancer refractory to first-line treatment with irinotecan and bolus 5-FU LV 21 ; . The study enrolled 821 patients and had a preplanned interim analysis after 450 patients were enrolled. At the time of this interim.
If you allowed a tiny drop of kerosene or carpet cleaning fluid to get into your pet's food every day, wouldn't you expect your pet to get sick? Why would you not expect to be sick with these solvents in your daily food? I imagine these solvents are just tiny amounts, introduced by sterilizing equipment, the manufacturing process, and adding flavor or color. Flavors and colors for food must be extracted somehow from the leaves or bark or beans from which they come. But until safe methods are invented, such food should be considered unsafe for human consumption or pets or livestock.
1. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol 2002; 29: 10718. Malafosse R, Penna C, Sa CA, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001; 12: 88794. Holen KD, Saltz LB. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol 2001; 2: 290 Kemeny N, Fata F. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 39 Schmoll HJ. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. Semin Oncol 2002; 29 5 Suppl 15 ; : 34 Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685 Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transpl Surg 1999; 5: 65 Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646 Martin JKJ, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 10227. Yoon SS, Tanabe KK. Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 1999; 4: 197208. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol 2001; 2: 418 Marinelli A, van der Velde CJ, Kuppen PJ, Franken HC, Souverijn JH, Eggermont AM. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 1990; 62: 891 Marinelli A, van Dierendonck JH, van Brakel GM, et al. Increasing.
Since the discovery by rosenberg and collaborators of the antitumor activity of cisplatin 35 years ago, three platinum antitumor drugs cisplatin, carboplatin and oxaliplatin ; have enjoyed a huge clinical and commercial hit.
|
